Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Register in der onkologischen Versorgungsforschung.

Klinkhammer-Schalke, M., Marschner, N., Hofstädter, F., 2012.

Der Onkologe 18, 142–150. doi:10.1007/s00761-011-2197-3

Abstract

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Der Onkologe
Registerübergreifend
2012
Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab?

Hartmann, H., Müller, J., Marschner, N., 2012.

J Clin Oncol 30, 3317–3318. doi:10.1200/JCO.2012.43.3409

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Journal of Clinical Oncology
Indikationsübergreifend
2012
Erneute Anti-HER2-Therapie mit Herceptin® beim ersten Rezidiv des HER2-positiven Mammakarzinoms-1. Interimsanalyse der nichtinterventionellen Studie (NIS) ML21589.

Hanker, L., Prange-Krex, G., Janssen, J., Reichert, D., Schröder, J., Förster, F., Schnohr, S., Hitschold, T., Indorf, M., Kaufmann, M., 2012.

Senologie 9(02). doi:10.1055/s-0032-1313426

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: -
Herceptin-NIS
2012
Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM.

Hadji, P., Kieback, D.G., Tams, J., Hasenburg, A., Ziller, M., 2012.

Ann Oncol 23, 2566–2572. doi:10.1093/annonc/mds055.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Annals of Oncology
TEAM
2012
Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.

Hadji, P., Kauka, A., Bauer, T., Tams, J., Hasenburg, A., Kieback, D.G., 2012.

Climacteric 15, 460–466. doi:10.3109/13697137.2011.647839

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Climacteric
TEAM
2012
How to further solidify data on systemic therapy in metastatic renal cell carcinoma (mRCC) in German mRCC registry on the treatment reality.

Goebell, P., Müller, L., Blumenstengel, K., Hübner, A., Lück, A., Koska, M., Marschner, N., 2012.

Eur Urol Suppl 2012;11,e79a DOI:10.1016/S1569-9056(12)60078-5

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: EAU / Journal: -
TNK
2012
Treatment of younger and elderly colorectal cancer patients in German outpatient centres – data from the clinical TKK registry.

Freier, W., Groschek, M., Schröder, J., von Verschuer, U., Jänicke, M., Marschner, N., 2012.

Onkologie 35 (suppl 6)(P193), 56. doi:10.1159/000170919

Abstract

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Onkologie
TKK
2012
Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.

Bossart, M., Becker, M., Hadji, P., Kieback, D.G., Hasenburg, A., 2012.

Anticancer Res 32, 3933–3938.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Anticancer Research
TEAM
2012
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study.

Bartlett, J.M.S., Bloom, K.J., Piper, T., Lawton, T.J., van de Velde, C.J.H., Ross, D.T., Ring, B.Z., Seitz, R.S., Beck, R.A., Hasenburg, A., Kieback, D., Putter, H., Markopoulos, C., Dirix, L., Seynaeve, C., Rea, D., 2012.

J Clin Oncol 30, 4477–4484. doi:10.1200/JCO.2012.42.8896

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Journal of Clinical Oncology
TEAM
2012
Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with sorafenib and paclitaxel by initial ramp-up dose escalation (PASO).

Overkamp, F., Steffens, C., Abenhardt, W., Lerchenmüller, C., Nusch, A., Göhler, T., Groschek, M., Hegewisch-Becker, S., Marschner, N., Rösel, S., Salat, C., Decker, T., 2011.

J Cancer Res Clin Oncol 138(Suppl.1)(0026), 62. doi:10.1007/s00432-011-1144-4

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Journal of Cancer Research and Clinical Oncology
PASO
2011